- Total Sovaldi (GILD -1.7%) prescriptions for the week ending May 16 amounted to 8,091 (-10.6% from the prior week), according to IMS data. New prescriptions fell 11.5% to 3,445.
- The numbers come amid an insurer backlash to Sovaldi's price tag ($84K for a 12-week course). In a blog post, insurer AHIP accuses Gilead of pricing Sovaldi "at an astronomical level that is not sustainable for consumers, innovation, or society."
- Wells Fargo (Outperform) isn't too worried about the IMS data. Though expecting Sovaldi demand to slow a bit as the year progresses, it still thinks the drug's 2014 U.S. sales could approach $9B.